Table 1. Inhibitors of JAK2 under clinical evaluation. (see also http://clinicaltrials.gov).
| Compound | Company | Additional Targets | Phase of study | |||
|---|---|---|---|---|---|---|
| I | II | III | IV | |||
| AZD1480 | Astra-Zeneca | JAK1, JAK3 | ||||
| CYT387 | YM Biosciences | JAK1, TYK2, JNK1, CDK2 | ||||
| Erlotinib | OsiPharma | EGFR | ||||
| Lestaurtinib (CEP-701) | Cephalon | FLT3, TrkA/B/C | currently suspended | |||
| LY2784544 | Elli-Lilly | |||||
| Ruxolitinib (INCB018424) | Novartis (Incyte) | JAK1 | ** | |||
| SAR302503 (TG101348) | Sanofi-Aventis (TargeGen) | FLT3, RET | ||||
| SB1518 | S*Bio | FLT3 | ||||
| XL019 | Exelixis | early termination | ||||
**
Ruxolitinib was approved by the FDA (U.S. Food and Drug Administration) for the treatment of intermediate or high-risk myelofibrosis in November 2011.